logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

SEFH joins the World Cancer Day recalling the importance of healthy habits and research

Source: www.immedicohospitalario.es

The arrival of advanced therapies, such as CAR-T cells, immunotherapy or other targeted treatments and their incorporation into the assistance protocols are being able to modify the course of many oncological and hematological pathologies and pose a new challenge for oncological pharmacists, which must be maintained continuously updated.

The Spanish Society of Hospital Pharmacy (SEFH) joins the World Cancer Day promoted by the World Health Organization, the International Cancer Research Center (CIIC) and the International Union Against Cancer (UICC) recalling the importance of promotion of healthy living habits and research.

Dr. José Antonio Marcos, from the Board of the SEFH, wanted to underline that, “on a day like February 4, World Cancer Day, it is necessary to remember that for the prevention of cancer it is essential to lead a lifestyle healthy. Toxic habits such as tobacco or alcohol abuse, together with factors such as obesity, sedentary lifestyle and sun exposure are related to the appearance of different types of cancer, so from our Society we remember that abandoning these risk factors , will mean a reduction in this disease and the reduction of possible relapses in these patients. ”

In addition, the SEFH is committed to work in the Society’s Oncology Pharmacy group (GEDEFO-SEFH) whose mission is to provide quality pharmaceutical care to achieve maximum clinical benefit and contribute to improving the health outcomes of cancer patients and Hematological in an efficient way. One of the key objectives of GEDEFO is to continue strengthening the role of the oncology pharmacist in the comprehensive care of cancer patients as members of the multidisciplinary team. In this sense, Dr. Estela Moreno, coordinator of GEDEFO, emphasizes that, “in recent years we have worked to improve information and education from pharmaceutical care consultations, redirected towards the CMO model (Capacity, Motivation, Opportunity), with the elaboration of information sheets adapted to the needs of the patients and with supporting documents for the pharmaceutical validation, which have a very positive impact on the quality of the care the patient receives ”.

Drug positioning and collaboration with patients

GEDEFO continues to collaborate in the positioning of new drugs and indications, based on scientific evidence and criteria of effectiveness, taking advantage of the specific training of its members on these issues. It has increased its collaboration with other scientific societies and patient associations and has been actively integrated into national and international medical societies such as the SEHOP group or the EBMT.

The arrival of advanced therapies, such as CAR-T cells, immunotherapy or other targeted treatments and their incorporation into the assistance protocols are being able to modify the course of many oncological and hematological pathologies and pose a new challenge for oncological pharmacists, which must be maintained continuously updated. “The training is key and we are committed to high-level activities such as the BPS specialization scholarships or the UIMP Master’s Degree in Immunooncology, in addition to the close collaboration between all members, seeking to learn from each other,” concludes Dr. Estela Moreno .

In Distefar, we believe that the continuous training of all health personnel is essential. Only then can we advance in therapies such as those for diseases such as cancer.

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.